ATAI ATAI Life Sciences

添加自选

1.570
+0.120+8.28%

收盘价 03/24 16:00 (美东)

1.650
+0.080+5.10%

盘后 20:01 (美东)

3.11亿总市值-1.69市盈率TTM

关于ATAI Life Sciences公司

ATAI Life Sciences NV 是一家临床阶段的生物制药公司，旨在改变精神疾病的治疗方式。其候选产品包括 COMP360/Psilocybin疗法、PCN-101/R-氯胺酮、RL-007/Compound、DMX-1002/Ibogaine、GRX-917/Deuterated etifoxine、VLS-01/DMT、EMP-01/MDMA 衍生物、RLS -01/Salvinorin A、KUR-101/Deuterated Mitragynine 和 DMX-1001/Noribogaine。该公司在美国和德国两个地区开展业务。

公司介绍

公司代码ATAI

公司名称ATAI Life Sciences

上市日期2021/06/18

发行价格15.00

成立日期2018

CEOMr. Srinivas G. Rao, M.D.,PhD

所属市场纳斯达克

员工数量63

年结日12-31

公司地址Wallstrasse 16

城市Berlin

省份柏林

国家德国

邮编10179

电话49-89-2153-9035

网址http://www.atai.life

董事高管

姓名
职务
年薪

Srinivas G. Rao, M.D.,PhD
Chief Executive Officer
173.47万

Dr. Gerd Kochendoerfer
Chief Operating Officer
--

Anne Nagengast Johnson
Chief Accounting Officer, Managing Director and Chief Financial Officer
117.02万

Glenn Frank Short
Chief Scientific Officer
--

Kevin James Craig
Chief Medical Officer
--

Dr. Sahil Kirpekar, M.D.
Chief Business Officer
--

Christian Angermayer
Chairman of the Supervisory Board
15.90万

Andrea Heslin Smiley
Member of the Supervisory Board
15.05万

Dr. Amir Kalali,M.D.
Member of the Supervisory Board
14.05万

Dr. Laurent Fischer, M.D.
Member of the Supervisory Board
--

Dr. Scott Braunstein, M.D.
Member of the Supervisory Board
--

Dr. Raymond Sanchez, M.D.
Member of the Supervisory Board
--

Sabrina Martucci Johnson
Member of the Supervisory Board
15.20万

ATAI ATAI Life Sciences

关于ATAI Life Sciences公司

公司介绍

董事高管

热门市场机会